not happy, page-44

First 44 Last

Share
Profile

Follow
Jazzasax

3,137 Posts.

383

19/04/16

23:32

Post #: 17548830
Share

Originally posted by rusty02 ↑

Ok Had a long chat with Kym,
Points of discussions, Cantrixil only.
*Toxicology as a stand alone document is very good. Management and team are excited.
*Now the package is being assessed by the IFD and the SDA for final approval from the Ethics committee.
*Clinical trials on track for 2nd half of the year and management will formally ANN to the market once formal approval is given.
*The toxicology report as a stand alone is not leveraged in any shape way or form until approval is given. In other words the Ethics committee agrees with management that we are good to proceed to the clinic. Then the formal announcement will be submitted. Management do not want to be in a position to ANN toxicology report to the market only to have issues later. This is where management see a re rate. When the pre clinical package is approved.
*Manufacturing is being perused concurrently to these events aimed at the 2nd half year clinical phase 1 so to is the clinical managers preparing clinical protocols.
*3rd party approval here is the key, until then we wait. Management are confident and still on track to have both manufacturing and clinical commissioning in readiness upon approval.
*Until then the company website and emailed updates is the tool to access research. (Not sure whether this is the right marketing strategy to entice new investor.)

Hope I make sense. Looking forward to the next 6 months again.
cheers.
M

Expand

It is bizarre to me and I don't doubt others that this company would not provide an update to the market that funds them!

Question is what is Garner doing???

Personally I would be getting very nervous if I was a Board member of NRT and any upcoming EGM's, keeping in mind we only require 5% to call one and that would be a piece of cake for some here.

Thankfully the medicine is our true asset!

NRT Price at posting: 13.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

ASX hits all time high out the gate on Friday trades following bullish US inflation data

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

There are more pages in this discussion • 28 more messages in this thread...

First 44 Last

Add KZA (ASX) to my watchlist

not happy, page-44

Top Stories

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Nimy to raise $1.21M to explore 'newsy' WA targets

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Featured News